Results for a study (NCT05834348) investigating the effectiveness of cancer medicines in patients with metastatic non-small cell lung cancer in Norway were posted on ClinicalTrials.gov on 2025-03-30. While atezolizumab was not an intervention in this specific trial, the study provides contextual data on treatment durations for anti-cancer drugs, with median durations ranging from 5 to 28 months.
Background
Atezolizumab (Tecentriq) is an immune checkpoint inhibitor approved for various indications, including non-small cell lung cancer. This study, titled 'A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway,' aimed to understand the effectiveness and treatment sequence of lung cancer medicines outside of traditional clinical trials. Metastatic non-small cell lung cancer (NSCLC) is a condition where lung cancer cells have spread to other parts of the body.
Trial design
The study (NCT05834348) was completed and enrolled 5279 participants aged 18 years or older with confirmed metastatic non-small cell lung cancer in Norway. The interventions studied included lorlatinib, crizotinib, brigatinib, ceritinib, and alectinib. The main purpose was to learn about the effectiveness and treatment sequence of these lung cancer medicines.
Key results
The study reported on the 'Duration of Treatment of Anti-cancer Drugs' within a 'Biomarker Cohort'. Median durations of treatment observed were: 11 months, 14 months, 9.4 months, 15.8 months, 20 months, 28 months, 11 months, 16 months, 7 months, 19 months, 5 months, and 18 months. These measurements represent the median duration of treatment for various anti-cancer drugs in this cohort.
What this means
The posted results offer insights into the real-world treatment durations of various anti-cancer drugs for patients with metastatic non-small cell lung cancer in Norway. While these specific durations are not attributed to atezolizumab, they contribute to the broader understanding of treatment patterns and effectiveness in the NSCLC landscape, a field where atezolizumab is also utilized. Clinicians and researchers can use this data to contextualize treatment expectations and outcomes for different therapeutic agents in this patient population.
Source
The information regarding these trial results was obtained from ClinicalTrials.gov, a public database of clinical studies. The results for study NCT05834348, titled 'A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway,' were posted on 2025-03-30 on clinicaltrials.gov.